• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket

    10/23/23 7:32:32 AM ET
    $AKU
    $BETS
    $CBIO
    $CFRX
    Medical Specialities
    Health Care
    Restaurants
    Consumer Discretionary
    Get the next $AKU alert in real time by email

    Gainers

    LumiraDx Limited (NASDAQ:LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub.

    Akumin Inc. (NASDAQ:AKU) shares rose 56.6% to $0.2285 in pre-market trading after the company reached an agreement with Stonepeak to become a private company.

    Next.e.GO N.V. (NASDAQ:EGOX) rose 47.5% to $2.08 in pre-market trading. Next.e.GO Mobile and Athena Consumer Acquisition announced the completion of their previously announced business combination.

    Textainer Group Holdings Limited (NYSE:TGH) shares gained 42.6% to $48.69 in pre-market trading after the company agreed to be acquired by Stonepeak for $7.4 billion.

    Harpoon Therapeutics, Inc. (NASDAQ:HARP) shares climbed 37.2% to $9.44 in pre-market trading after the company disclosed Updated interim tolerability and response data from Phase 1/2 clinical trial of T Cell engager HPN328 at ESMO Congress 2023.

    The Alkaline Water Company Inc. (NASDAQ:WTER) shares rose 35% to $0.2699 in pre-market trading after falling 14% on Friday.

    Motus GI Holdings, Inc. (NASDAQ:MOTS) gained 29.7% to $0.6226 in pre-market trading.

    LM Funding America, Inc. (NASDAQ:LMFA) shares jumped 18.8% to $0.5468 in pre-market trading after jumping 12% on Friday.

    Roivant Sciences Ltd. (NASDAQ:ROIV) rose 15.2% to $11.13 in pre-market trading. Roche agreed to acquire Telavant, including rights to novel TL1A-directed antibody (RVT-3101), from Roivant for $7.1 billion.

    Bit Brother Limited (NASDAQ:BETS) shares rose 12.2% to $0.5490 in pre-market trading.

    Losers

    XORTX Therapeutics Inc. (NASDAQ:XRTX) dipped 21.7% to $0.50 in pre-market trading after jumping more than 100% on Friday.

    Troika Media Group, Inc. (NASDAQ:TRKA) shares fell 20.9% to $0.87 in pre-market trading after reporting financial results for the quarter ended June 30, 2023.

    Treasure Global Inc. (NASDAQ:TGL) shares fell 18.8% to $0.3042 in pre-market trading after gaining 14% on Friday.

    TD Holdings, Inc. (NASDAQ:GLG) shares fell 18.8% to $0.0723 in pre-market trading after dipping 13% on Friday.

    WANG & LEE GROUP, Inc. (NASDAQ:WLGS) fell 18.3% to $0.62 in pre-market after gaining over 38% on Friday.

    Golden Sun Education Group Limited (NASDAQ:GSUN) shares fell 13.6% to $0.4510 in pre-market trading after declining 5% on Friday.

    FaZe Holdings Inc. (NASDAQ:FAZE) shares fell 12.1% to $0.1750 in pre-market trading. GameSquare Holdings and FaZe Holdings recently entered into a definitive agreement pursuant to which GameSquare will acquire FaZe Clan in an arm's length all-stock transaction.

    ContraFect Corporation (NASDAQ:CFRX) shares fell 11.9% to $0.3172 in pre-market trading after declining 10% on Friday. The company recently reported FDA clearance of CF-370 IND application to proceed with Phase 1 clinical study.

    Catalyst Biosciences, Inc. (NASDAQ:CBIO) fell 11.7% to $0.4414 in pre-market trading after climbing around 25% on Friday.

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) fell 10.5% to $0.2417 in pre-market trading after gaining 10% on Friday.

    Now Read This: Fear Among US Investors Is Growing: Here's Why

    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU
    $BETS
    $CBIO
    $CFRX

    CompanyDatePrice TargetRatingAnalyst
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Roivant Sciences Ltd.
    $ROIV
    9/2/2025$16.00Buy
    Citigroup
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    LM Funding America Inc.
    $LMFA
    8/15/2025$5.00Neutral → Buy
    H.C. Wainwright
    Crescent Biopharma Inc.
    $CBIO
    8/11/2025$25.00Buy
    H.C. Wainwright
    Crescent Biopharma Inc.
    $CBIO
    7/14/2025$27.00Outperform
    Wedbush
    Roivant Sciences Ltd.
    $ROIV
    7/10/2025$19.00Buy
    Goldman
    More analyst ratings

    $AKU
    $BETS
    $CBIO
    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Crescent Biopharma with a new price target

    Guggenheim initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $35.00

    1/21/26 8:54:45 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Roivant Sciences with a new price target

    Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00

    9/2/25 8:40:38 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKU
    $BETS
    $CBIO
    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

    Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today a

    2/25/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout

    NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deployment of INBS's fingerprint drug screening technology across its UK operations. The partnership reflects a shift from third-party testing services to an in-house solution, driven by superior hygiene protocols, operational efficiency, and demonstrated cost savings, validated through joint Return on Investment ("ROI") a

    2/24/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Treasure Global Reports Second Quarter Year 2026 Financial Results

    KUALA LUMPUR, Malaysia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treasure Global Inc. (NASDAQ:TGL) ("Treasure Global" or the "Company"), a Southeast Asia–anchored technology company, today announced its financial results for the second quarter ended December 31, 2025. Key Financial Highlights Revenue for the second quarter was USD1.08 million, a significant increase from USD0.30 million in Q2 FY2025, driven by continued growth in gift-card ("E-voucher") transactions on the ZCITY platform.Net loss was USD3.11 million, compared to USD0.23 million in Q2 FY2025, partially offset by USD4.63 million in favorable fair-value adjustments of derivative liabilities.Loss per share was USD(3.47), compared t

    2/24/26 8:35:00 AM ET
    $TGL
    Real Estate

    $AKU
    $BETS
    $CBIO
    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Pulik Richard covered exercise/tax liability with 1,000 shares, decreasing direct ownership by 0.42% to 238,413 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    2/24/26 6:43:53 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & Immunovant CEO Venker Eric covered exercise/tax liability with 7,051 shares, decreasing direct ownership by 0.43% to 1,647,546 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    2/24/26 6:43:18 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and Vant Chair Torti Frank exercised 3,000,000 shares at a strike of $3.85 and sold $82,039,460 worth of shares (3,000,000 units at $27.35) (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    2/23/26 8:40:19 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKU
    $BETS
    $CBIO
    $CFRX
    SEC Filings

    View All

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    2/25/26 9:15:25 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Treasure Global Inc.

    10-Q - TREASURE GLOBAL INC (0001905956) (Filer)

    2/23/26 3:49:53 PM ET
    $TGL
    Real Estate

    SEC Form EFFECT filed by XORTX Therapeutics Inc.

    EFFECT - XORTX Therapeutics Inc. (0001729214) (Filer)

    2/18/26 12:15:12 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKU
    $BETS
    $CBIO
    $CFRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/18/25 7:28:11 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graham Andrew L. bought $25,764 worth of shares (10,000 units at $2.58), increasing direct ownership by 137% to 17,303 units (SEC Form 4)

    4 - LM FUNDING AMERICA, INC. (0001640384) (Issuer)

    11/19/24 4:32:27 PM ET
    $LMFA
    Finance: Consumer Services
    Finance

    $AKU
    $BETS
    $CBIO
    $CFRX
    Leadership Updates

    Live Leadership Updates

    View All

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LM Funding America Announces September 2025 Production and Operational Update

    - Bitcoin treasury as of September 30, 2025 valued at $34.7 million or $2.24 per share1 TAMPA, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ:LMFA) ("LM Funding" or the "Company"), a Bitcoin treasury and mining company, today announced its preliminary, unaudited Bitcoin mining and operational update for the month ended September 30, 2025. MetricAugust 2025September 2025- Bitcoin2  - Mined, net5.85.9- Sold(9.0)(12.5)- Purchased164-- Service Fee-(0.1)- Bitcoin HODL311.2304.5- Machines2  - Oklahoma4,3204,320- Mississippi-2,376- Storage1,218795- Total Machines5,5387,491- Hashrate (EH/s2)  - Oklahoma0.480.48- Mississippi3-0.22- Energized0.480.70- Monthly Average0.390

    10/8/25 8:30:00 AM ET
    $LMFA
    Finance: Consumer Services
    Finance

    Treasure Global Appoints Michael Chan as Executive Director to Strengthen Board and Drive Strategic Growth

    KUALA LUMPUR, Malaysia, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Treasure Global Inc. (NASDAQ:TGL) ("Treasure Global" or the "Company"), a Southeast Asia–anchored technology company, today announced the appointment of Michael Chan as an Executive Director of its Board of Directors, effective immediately. Michael previously served as Chief Financial Officer of Treasure Global, where he contributed to key financial and strategic initiatives, including capital management and operational optimization. After a period of personal pursuits, he has been invited to rejoin the Company's leadership at the Board level to strengthen governance and provide strategic guidance as Treasure Global advances its g

    9/26/25 3:00:00 PM ET
    $TGL
    Real Estate

    $AKU
    $BETS
    $CBIO
    $CFRX
    Financials

    Live finance-specific insights

    View All

    Treasure Global Reports Second Quarter Year 2026 Financial Results

    KUALA LUMPUR, Malaysia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treasure Global Inc. (NASDAQ:TGL) ("Treasure Global" or the "Company"), a Southeast Asia–anchored technology company, today announced its financial results for the second quarter ended December 31, 2025. Key Financial Highlights Revenue for the second quarter was USD1.08 million, a significant increase from USD0.30 million in Q2 FY2025, driven by continued growth in gift-card ("E-voucher") transactions on the ZCITY platform.Net loss was USD3.11 million, compared to USD0.23 million in Q2 FY2025, partially offset by USD4.63 million in favorable fair-value adjustments of derivative liabilities.Loss per share was USD(3.47), compared t

    2/24/26 8:35:00 AM ET
    $TGL
    Real Estate

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

    Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou

    2/6/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKU
    $BETS
    $CBIO
    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Intelligent Bio Solutions Inc.

    SC 13G - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 4:31:30 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care